Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19285679 | 1.00 | PTGER1 (0.52) | PTGER1MRGPRX4NPC1KDM1AFOLH1 | |
| SCHEMBL19285699 | 0.88 | KDM1A (0.50) | PTGER1MRGPRX4NPC1KDM1AFOLH1 | |
| SCHEMBL28316118 | 0.88 | KDM1A (0.50) | PTGER1MRGPRX4NPC1KDM1AFOLH1 | |
| SCHEMBL31388811 | 0.85 | NPC1 (0.51) | PTGER1MRGPRX4NPC1KDM1AFOLH1 | |
| SCHEMBL1495302 | 0.85 | MRGPRX4 (0.55) | PTGER1MRGPRX4FOLH1 | |
| SCHEMBL1495326 | 0.85 | MRGPRX4 (0.54) | PTGER1MRGPRX4NPC1FOLH1 | |
| SCHEMBL28496127 | 0.85 | FOLH1 (0.49) | PTGER1MRGPRX4NPC1FOLH1NR4A1 | |
| SCHEMBL2897224 | 0.83 | MRGPRX4 (0.62) | PTGER1MRGPRX4NPC1KDM1AFOLH1 | |
| SCHEMBL14829578 | 0.81 | PTGER1 (0.47) | PTGER1MRGPRX4NPC1S1PR5 | |
| SCHEMBL9267862 | 0.80 | MRGPRX4 (0.52) | PTGER1MRGPRX4NPC1FOLH1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-110891566-B | Synthesis method and synthesis intermediate | 塔克西斯医药股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | PTGER1 4023/4885MRGPRX4 1186/4885NPC1 334/4885 |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LPL | PTGER1 2238/4885MRGPRX4 917/4885NPC1 300/4885 |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | MGLL, PNLIP, LIPC | PTGER1 4023/4885MRGPRX4 1186/4885NPC1 334/4885 |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | PTGER1 4023/4885MRGPRX4 1186/4885NPC1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.